How do I install the Esa Pa Interpret Postural Stim skill?

Run npx skillmds@latest add dromlakhani/esa-pa-interpret-postural-stim in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Esa Pa Interpret Postural Stim safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Esa Pa Interpret Postural Stim?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Esa Pa Interpret Postural Stim free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Esa Pa Interpret Postural Stim?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Esa Pa Interpret Postural Stim by dromlakhani

Name: Esa Pa Interpret Postural Stim
Rating: 4.5 (4 reviews)
Author: dromlakhani

Esa Pa Interpret Postural Stim

Interprets the postural stimulation test to detect angiotensin II‑unresponsive aldosterone‑producing adenoma (APA) or familial hyperaldosteronism type I (FH‑I) when aldosterone fails to rise with upright posture. Triggered by clinical cues such as “postural stimulation test shows no aldosterone increase”, “suspected APA with non‑responsive aldosterone”, or “evaluating FH‑I in young patients with early‑onset hypertension and hypokalemia”.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Interpret Postural Stimulation Test for PA

STEP 1 — Gather Information

Measure supine plasma aldosterone concentration (PAC), then have the patient stand upright for at least 2 hours and measure PAC again; record age, family history of hypertension/stroke before age 40, presence of hypokalemia, and current medications (especially MR antagonists, ACEi/ARBs).

STEP 2 — Rule In / Rule Out

If upright PAC shows a significant rise (e.g., ≥2‑fold increase or >20 % absolute increase) compared with supine → angiotensin II‑responsive phenotype (rule out angiotensin II‑unresponsive subtypes). If upright PAC does not rise significantly → rule in angiotensin II‑unresponsive APA or FH‑I.

STEP 3 — Classify or Stratify

Among non‑responsive cases, assess for FH‑I: age <20 years, family history of early‑onset hypertension or stroke, or severe hypokalemia → suspect FH‑I and plan genetic testing; otherwise suspect angiotensin II‑unresponsive APA.

STEP 4 — Decide

If FH‑I suspected, order genetic testing for the CYP11B1/CYP11B2 chimeric gene (GRA) and consider low‑dose glucocorticoid therapy; if APA suspected, proceed to adrenal venous sampling (AVS) to confirm lateralization, or if AVS is unsuccessful, consider unilateral adrenalectomy based on a unilateral adrenal mass on CT.

Clinical Guardrails / Mimics / Pitfalls

Do not interpret the test in patients taking MR antagonists, ACE inhibitors, ARBs, or with severe uncontrolled hypertension, as these can blunt aldosterone response. Lack of aldosterone rise may also occur in idiopathic hyperaldosteronism (IHA) with diurnal variation; avoid confusing IHA with FH‑I without genetic confirmation. False‑negative results are possible if the standing period is insufficient or if the patient has recent sodium loading.

Concrete Clinical Example

A 22‑year‑old woman with hypertension, hypokalemia, and elevated ARR undergoes postural stimulation test: supine PAC 12 ng/dL, upright PAC 13 ng/dL (no significant rise). She has a brother diagnosed with hypertension at age 30. FH‑I is suspected; genetic testing confirms a CYP11B1/CYP11B2 chimera, and she is started on low‑dose dexamethasone.

Source: The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-4061

---name: esa-pa-interpret-postural-stimdescription: Interprets the postural stimulation test to detect angiotensin II‑unresponsive aldosterone‑producing adenoma (APA) or familial hyperaldosteronism type I (FH‑I) when aldosterone fails to rise with upright posture. Triggered by clinical cues such as “postural stimulation test shows no aldosterone increase”, “suspected APA with non‑responsive aldosterone”, or “evaluating FH‑I in young patients with early‑onset hypertension and hypokalemia”.---# Interpret Postural Stimulation Test for PA## STEP 1 — Gather InformationMeasure supine plasma aldosterone concentration (PAC), then have the patient stand upright for at least 2 hours and measure PAC again; record age, family history of hypertension/stroke before age 40, presence of hypokalemia, and current medications (especially MR antagonists, ACEi/ARBs).## STEP 2 — Rule In / Rule OutIf upright PAC shows a significant rise (e.g., ≥2‑fold increase or >20 % absolute increase) compared with supine → angiotensin II‑responsive phenotype (rule out angiotensin II‑unresponsive subtypes). If upright PAC does **not** rise significantly → rule in angiotensin II‑unresponsive APA or FH‑I.## STEP 3 — Classify or StratifyAmong non‑responsive cases, assess for FH‑I: age <20 years, family history of early‑onset hypertension or stroke, or severe hypokalemia → suspect FH‑I and plan genetic testing; otherwise suspect angiotensin II‑unresponsive APA.## STEP 4 — DecideIf FH‑I suspected, order genetic testing for the CYP11B1/CYP11B2 chimeric gene (GRA) and consider low‑dose glucocorticoid therapy; if APA suspected, proceed to adrenal venous sampling (AVS) to confirm lateralization, or if AVS is unsuccessful, consider unilateral adrenalectomy based on a unilateral adrenal mass on CT.## Clinical Guardrails / Mimics / PitfallsDo not interpret the test in patients taking MR antagonists, ACE inhibitors, ARBs, or with severe uncontrolled hypertension, as these can blunt aldosterone response. Lack of aldosterone rise may also occur in idiopathic hyperaldosteronism (IHA) with diurnal variation; avoid confusing IHA with FH‑I without genetic confirmation. False‑negative results are possible if the standing period is insufficient or if the patient has recent sodium loading.## Concrete Clinical ExampleA 22‑year‑old woman with hypertension, hypokalemia, and elevated ARR undergoes postural stimulation test: supine PAC 12 ng/dL, upright PAC 13 ng/dL (no significant rise). She has a brother diagnosed with hypertension at age 30. FH‑I is suspected; genetic testing confirms a CYP11B1/CYP11B2 chimera, and she is started on low‑dose dexamethasone.**Source:** The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2015-4061

Frequently asked questions